CVA Family Office LLC Sells 202 Shares of Becton, Dickinson and Company (NYSE:BDX)

CVA Family Office LLC trimmed its holdings in Becton, Dickinson and Company (NYSE:BDX) by 42.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 270 shares of the medical instruments supplier’s stock after selling 202 shares during the quarter. CVA Family Office LLC’s holdings in Becton, Dickinson and Company were worth $63,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Hilltop National Bank boosted its position in shares of Becton, Dickinson and Company by 8.0% in the second quarter. Hilltop National Bank now owns 1,557 shares of the medical instruments supplier’s stock valued at $364,000 after acquiring an additional 115 shares during the period. Apella Capital LLC boosted its position in shares of Becton, Dickinson and Company by 27.3% in the second quarter. Apella Capital LLC now owns 1,305 shares of the medical instruments supplier’s stock valued at $289,000 after acquiring an additional 280 shares during the period. Somerset Trust Co boosted its position in shares of Becton, Dickinson and Company by 1.2% in the second quarter. Somerset Trust Co now owns 14,517 shares of the medical instruments supplier’s stock valued at $3,393,000 after acquiring an additional 174 shares during the period. Kingswood Wealth Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 85.3% in the second quarter. Kingswood Wealth Advisors LLC now owns 1,714 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 789 shares during the period. Finally, Value Partners Investments Inc. boosted its position in shares of Becton, Dickinson and Company by 28.8% in the second quarter. Value Partners Investments Inc. now owns 1,691 shares of the medical instruments supplier’s stock valued at $395,000 after acquiring an additional 378 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded down $2.89 during midday trading on Wednesday, reaching $232.62. 1,096,652 shares of the company traded hands, compared to its average volume of 1,457,544. The firm has a market cap of $67.23 billion, a PE ratio of 51.24, a PEG ratio of 2.06 and a beta of 0.42. The stock’s 50-day simple moving average is $233.22 and its 200-day simple moving average is $236.30. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $284.48. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.97 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period last year, the business earned $2.96 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 13.06 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Monday, September 9th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 83.70%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Evercore ISI reduced their target price on Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Raymond James reduced their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Citigroup reduced their target price on Becton, Dickinson and Company from $260.00 to $255.00 and set a “neutral” rating for the company in a research report on Wednesday, July 10th. Finally, The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Insider Activity

In other news, EVP Roland Goette sold 3,300 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the completion of the sale, the executive vice president now directly owns 14,608 shares in the company, valued at $3,457,713.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Roland Goette sold 3,300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $236.70, for a total value of $781,110.00. Following the completion of the sale, the executive vice president now directly owns 14,608 shares in the company, valued at $3,457,713.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Thomas J. Spoerel sold 300 shares of Becton, Dickinson and Company stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total value of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares of the company’s stock, valued at $472,876.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,900 shares of company stock worth $1,634,112. 0.31% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.